


UNDERSTANDING SYSTEMIC MASTOCYTOSIS

WHAT IS SM?


Systemic mastocytosis (SM) is a rare disease estimated to occur in approximately 32,000 adults in the U.S.¹ **It is a disorder where abnormal mast cells – a type of white blood cell that plays an important role in managing immune responses – accumulate in different parts of the body such as the skin, heart, gut, bones and other organs.**²

Most of those affected by SM have indolent SM, a type of non-advanced SM, and a minority of patients have advanced SM.^{1,2}



WHAT CAUSES SM?

SM is caused by the activation of the KIT receptor protein. SM is driven by the KIT D816V mutation in about 95% of cases.²⁻⁴



HOW IS SM DIAGNOSED?

Several tests may be used to determine if someone has SM, including:⁵



Tryptase tests measure the amount of serum tryptase (an enzyme released by mast cells) in your blood.



High-sensitivity KIT D816V blood testing can support an SM diagnosis by identifying a genetic mutation that is a primary underlying cause of the disease in ~95% of SM cases.^{3,4}




Biopsies in the skin, bone marrow, or other organs are used to measure the number of mast cells within tissue and detect abnormalities.

Given the variety of SM symptoms, along with the rarity of the disease, patients may be misdiagnosed.⁵⁻⁷

WHAT ARE THE SYMPTOMS OF SM?


People living with SM may experience more than 20 symptoms.^{2,8} These symptoms can be chronic (lifelong), unpredictable and debilitating,^{9,10} and some may be potentially life threatening - such as anaphylaxis.^{2,11,12} Common symptoms include:



Not a comprehensive list of all symptoms reported. Symptoms may vary from person to person.

WHAT MAY TRIGGER SM SYMPTOMS?

Triggers, or what may cause symptoms, can vary widely for those living with SM and change over time.¹³ People with SM may protect themselves against unpredictable triggers.^{2,14} Common triggers include:



PATIENT-REPORTED RESULTS INDICATED THAT SM SYMPTOMS MAY GREATLY IMPACT DAILY LIFE.¹⁵

In a Blueprint Medicines' study, U.S. adults with a self-reported SM diagnosis (N=56) completed an online survey of 100 items, including the 12-item Short-Form Health Survey, the ISM Symptom Assessment Form, and the Work Productivity and Activity Impairment Questionnaire, as well as questions about disease impact.¹⁵



WHAT ARE THE CHALLENGES OF MANAGING SM?

Historically, people with SM have had limited treatment options to address their disease, and treatments were limited to symptom relief.²

86% of patients with indolent SM (N=37) reported moderate to severe symptom burden despite taking a median of 3 over the counter and 2 prescription medications for their indolent SM symptoms.¹⁶

Visit www.ItsSMthing.com for more information about SM

References: 1. Cohen, SS. Epidemiology of systemic mastocytosis in Denmark. 2014 March; 166: 521-528. 2. Gilreath JA, Tchertanov L and Deininger MW, 'Novel approaches to treating advanced systemic mastocytosis', *Clin Pharmacol* 2019;11:77-92. 3. Kristensen T, Vestergaard H, Moller MB. 'Improved detection of the KIT D816V mutation in patients with systemic mastocytosis using a quantitative and highly sensitive real-time qPCR assay'. *J Mol Diagn*. 2011;13(2):180-188. 4. Garcia-Montero AC et al. 'KIT mutation in mast cells and other bone marrow hematopoietic cell lineages in systemic mast cell disorders: a prospective study of the Spanish Network on Mastocytosis (REMA) in a series of 113 patients'. *Blood*. 2006;108(7):2366-2372. 5. Shomali 2018, 'The new tool "KIT" in advanced systemic mastocytosis'. Hematology Am Soc Hematol Educ Program. 2018;2018(1):127-136. 6. Valent, P. 'Standards and standardization in mastocytosis: consensus statements on diagnostics, treatment recommendations and response criteria'. *European Journal of Clinical Investigation*. 2007;37(6):435-453. 7. Castells M, 'Mastocytosis (cutaneous and systemic) in Adults'. July 2021. 8. Theoharides, et al. 'Mast Cells, Mastocytosis, and Related Disorders'. *N Engl J Med* 2015;373(2):163-172. 9. Akin, C. Cham, 'Mastocytosis. A Comprehensive Guide'. Switzerland: Springer Nature Switzerland AG 2020. 10. Jensen B, et al. 'Everyday life and mastocytosis from a patient perspective - a qualitative study', *J Clin Nurs* 2018;28:1114-1124. 11. Lim K-H, et al. 'Systemic mastocytosis in 342 consecutive adults: survival studies and prognostic factors', *Blood* 2009;113(23):5727-5136. 12. Sperr WR, et al. 'International prognostic scoring system for mastocytosis (IPSM): a retrospective cohort study'. *Lancet* 2019;6(12):e638-e649. 13. The Mastocytosis Society (TMS). Symptoms and Triggers of Mast cell activation. 2020. 14. Pardanani A, 'Systemic mastocytosis in adults: 2021 Update on diagnosis, risk stratification and management'. *Am J Hematol* 2021;96(4):508-525. 15. Mesa R, 'Patient-reported outcomes among patients with systemic mastocytosis in routine clinical practice: Results of the TouchStone SM Patient Survey'. *Cancer*. March 2022. 16. Data on file. Blueprint Medicines Corporation, Cambridge, MA. 2023.